A multicentre randomised phase III trial comparing atezolizumab plus bevacizumab and standard chemotherapy versus bevacizumab and standard chemotherapy as first-line treatment for advanced malignant pleural mesothelioma

BEAT-meso: Bevacizumab and atezolizumab in malignant pleural mesothelioma

Chemotherapy with cisplatin plus pemetrexed is the currently approved standard as first-line therapy for patients with malignant pleural mesothelioma. The best survival outcome to date has been achieved by combining standard chemotherapy with bevacizumab. However, new treatment strategies are needed in order to further improve outcome. Immunotherapy has achieved promising results in a subset of patients with PD-L1-positive tumours in the second-line setting.

The aim of the BEAT-meso trial was to address whether the addition of the anti-PD-L1 antibody atezolizumab given in combination with standard chemotherapy plus bevacizumab improves the outcome in advanced treatment-naïve malignant pleural mesothelioma patients.

Trial Scheme

Trial Information

Primary Endpoint:
Overall survival
Secondary Endpoints:
Progression-free survival (investigator assessed)
Objective Response rate
Disease control rate
Time to treatment failure
Duration of response
Safety and tolerability
Patient reported outcome
Quality of life
Target Sample Size:
400 randomised patients
Protocol Release Date:
7 September 2018
Trial Activation Date:
12 April 2019
First Patient In:
30 April 2019
Accrual Closure Date:
07 March 2022

Trial Organisation

Trial Chair:
Enriqueta Felip
Trial Co-Chair:
Sanjay Popat
ETOP IBCSG Partners Foundation
Coordinating Group:
ETOP IBCSG Partners Foundation
Participating Groups:
Swiss Group for Clinical Cancer Research (SAKK) and Spanish Lung Cancer Group (SLCG)
Participating Countries:
Belgium, France, Italy, Spain, Switzerland, United Kingdom
EudraCT number: 2018-002180-25
ClinicalTrials.gov: NCT03762018


ETOP IBCSG Partners Foundation
Effingerstrasse 33
3008 Bern, Switzerland

Log in to gain access to trial related material.

Log in